IR@PKUHSC  > 北京大学第二临床医学院  > 风湿免疫科
学科主题临床医学
Etoricoxib versus indometacin in the treatment of Chinese patients with acute gouty arthritis: a randomized double-blind trial
Li Ting1; Chen Shun-le1; Dai Qing1; Han Xing-hai2; Li Zhan-guo3; Wu Dong-hai4; Zhang Xiao5; Gu Jie-ruo6; Yang Nan-ping7; Sun Ling-yun8; Zhang Miu-jia9; Li Xing-fu10; Bao Chun-de1
关键词gout arthritis etoricoxib indometacin cyclooxygenase-2
刊名CHINESE MEDICAL JOURNAL
2013-05-20
DOI10.3760/cma.j.issn.0366-6999.20122892
126期:10页:1867-1871
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
研究领域[WOS]General & Internal Medicine
关键词[WOS]ORAL INDOMETHACIN ; CLINICAL-TRIAL ; CELECOXIB ; EFFICACY ; CYCLOOXYGENASE-2 ; MANAGEMENT ; DICLOFENAC ; OSTEOARTHRITIS ; ROFECOXIB ; INHIBITOR
英文摘要

Background Acute gout is an intensely painful, inflammatory arthritis. Although the non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for this condition, the efficacy is based on only a few studies, particularly in China. We tried to assess the safety and efficacy of etoricoxib in the treatment of acute gouty arthritis in China.

Methods A randomized, double-blind, active comparator study was conducted at 10 sites in China. Patients (n=178; >= 18 years of age) with acute gouty attack (<48 hours) were treated for 5 days with etoricoxib (120 mg/d; n=89) or indometacin (75 mg twice daily; n=89). The primary efficacy end point was self-assessed pain in the affected joint (0-4 point Likert scale) from days 2-5. Secondary end points included investigator assessments of tenderness and swelling, patient/investigator global assessments of response to therapy, and patients discontinuing treatment. Safety was assessed by adverse events (AEs).

Results Etoricoxib and indometacin had comparable primary and secondary end points. Mean change difference from baseline from days 2-5 was 0.03 (95% confidence interval (CI) -0.19 to 0.25; P=0.6364), which fell within the prespecified comparative bounds of -0.5 to 0.5. No severe AEs were associated with etoricoxib use. Non-severe AEs were mainly digestive and general, and most (73.7%) were mild, although they caused withdrawal of two subjects in the etoricoxib group, due to bilateral renal calculi and uronephrosis of the left kidney (unrelated to etoricoxib) and fever and chills (potentially etoricoxib-related). Overall, AEs were similar, although the absolute number of AEs in the etoricoxib group (n=31) was less than the indometacin group (n=34).

Conclusions Etoricoxib (120 mg once daily) is effective in treating acute gout, is generally safe and well-tolerated, and is comparable in efficacy to indometacin (75 mg twice daily).

语种英语
WOS记录号WOS:000319529200013
资助机构Merck Sharp &amp ; Dohme, a subsidiary of Merck Company, Inc.
引用统计
被引频次:9[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/58509
专题北京大学第二临床医学院_风湿免疫科
作者单位1.Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Rheumatol, Shanghai 200001, Peoples R China
2.Changhai Hosp, Dept Rheumatol, Shanghai 200438, Peoples R China
3.Beijing Univ, Peoples Hosp, Dept Rheumatol, Beijing 100044, Peoples R China
4.China Japan Friendship Hosp, Dept Rheumatol, Beijing 100029, Peoples R China
5.Guangdong Prov Peoples Hosp, Dept Rheumatol, Guangzhou 510120, Guangdong, Peoples R China
6.Sun Yat Sen Univ, Affiliated Hosp 3, Dept Rheumatol, Guangzhou 510630, Guangdong, Peoples R China
7.Sichuan Univ, West China Hosp, Dept Rheumatol, Chengdu 610041, Sichuan, Peoples R China
8.Nanjing Drum Tower Hosp, Dept Rheumatol, Nanjing 210008, Jiangsu, Peoples R China
9.Jiangsu Prov Hosp, Dept Rheumatol, Nanjing 210029, Jiangsu, Peoples R China
10.Qilu Hosp, Dept Rheumatol, Jinan 250012, Shandong, Peoples R China
推荐引用方式
GB/T 7714
Li Ting,Chen Shun-le,Dai Qing,et al. Etoricoxib versus indometacin in the treatment of Chinese patients with acute gouty arthritis: a randomized double-blind trial[J]. CHINESE MEDICAL JOURNAL,2013,126(10):1867-1871.
APA Li Ting.,Chen Shun-le.,Dai Qing.,Han Xing-hai.,Li Zhan-guo.,...&Bao Chun-de.(2013).Etoricoxib versus indometacin in the treatment of Chinese patients with acute gouty arthritis: a randomized double-blind trial.CHINESE MEDICAL JOURNAL,126(10),1867-1871.
MLA Li Ting,et al."Etoricoxib versus indometacin in the treatment of Chinese patients with acute gouty arthritis: a randomized double-blind trial".CHINESE MEDICAL JOURNAL 126.10(2013):1867-1871.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Li Ting]的文章
[Chen Shun-le]的文章
[Dai Qing]的文章
百度学术
百度学术中相似的文章
[Li Ting]的文章
[Chen Shun-le]的文章
[Dai Qing]的文章
必应学术
必应学术中相似的文章
[Li Ting]的文章
[Chen Shun-le]的文章
[Dai Qing]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。